Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis

Rituximab (RTX) may benefit patients with glomerular disease who suffer from focal segmental glomerular sclerosis (FSGS) or minimal change disease (MCD). Here, we have described our experience treating 6 FSGS and 9 MCD patients with steroid-dependent/refractory nephrotic syndrome (NS) with RTX. Pati...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Ren, Hong, Lin, Li, Shen, Pingyan, Li, Xiao, Xie, Jingyuan, Pan, Xiaoxia, Zhang, Wen, Chen, Nan
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2017
Teme:
Research Paper: Immunology
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5706808/
https://ncbi.nlm.nih.gov/pubmed/29212162
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.21833
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items